Comment on “Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment”

References

• Chen, J., Ho, M., Lee, K., Song, Y., Fang, Y., Goldstein, B.A., He, W., Irony, T., Jiang, Q., van der Laan, M., Lee, H., Lin, X., Meng, Z., Mishra-Kalyani, P., Rockhold, F., Wang, H., and White, R. (2021), “The Current Landscape in Biostatistics of Real-World Data and Evidence: Clinical Study Design and Analysis,” Statistics in Biopharmaceutical Research. DOI: 10.1080/19466315.2021.1883474.
   Web of Science ®Google Scholar
• Daniel, R., Zhang, J., and Farewell, D. (2021), “Making Apples From Oranges: Comparing Noncollapsible Effect Estimators and Their Standard Errors After Adjustment for Different Covariate Sets,” Biometrical Journal, 63, 528–557. DOI: 10.1002/bimj.201900297.
   PubMed Web of Science ®Google Scholar
• Desai, R. J., and Franklin, J. M. (2019), “Alternative Approaches for Confounding Adjustment in Observational Studies Using Weighting Based on the Propensity Score: A Primer for Practitioners,” BMJ, 367, 15657. DOI: 10.1136/bmj.l5657.
   Google Scholar
• FDA Center for Drug Evaluation and Research (2019a) Multi-discipline review. NDA 212306 XPOVIO (Selinexor), available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212306Orig1s000MultidisciplineR.pdf
   Google Scholar
• FDA Center for Drug Evaluation and Research (2019b), Multi-discipline review. NDA 212018 BALVERSA (Erdafitinib), available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212018Orig1s000MultidisciplineR.pdf
   Google Scholar
• FDA Center for Drug Evaluation and Research (2019c), Multi-discipline review. BLA 761163 Monjuvi (Tafasitamab-cxix), available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761163Orig1s000MultidisciplineR.pdf
   Google Scholar
• García-Albéniz, X., Hsu, J., and Hernán, M.A. (2017), “The Value of Explicitly Emulating a Target Trial When Using Real World Evidence: An Application to Colorectal Cancer Screening,” European Journal of Epidemiology, 32, 495–500. DOI: 10.1007/s10654-017-0287-2.
   PubMed Web of Science ®Google Scholar
• Ghadessi, M., Tang, R., Zhou, J., Liu, R., Wang, C., Toyoizumi, K., Zhang, L., Deng, C. Q., and Beckman, R. A. (2020), “A roadmap to Using Historical Controls in Clinical Trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG),” Orphanet Journal of Rare Diseases, 15, 69.
   PubMed Web of Science ®Google Scholar
• Goetghebeur, E., le Cessie, S., De Stavola, B., Moodie, E. E. M., and Waernbaum, I. (2020), “Formulating Causal Questions and Principled Statistical Answers,” Statistics in Medicine, 39, 4922–4948. DOI: 10.1002/sim.8741.
   PubMed Web of Science ®Google Scholar
• Goodman, S. N., Schneeweiss. S., and Baiocchi, M. (2017), “Using Design Thinking to Differentiate Useful From Misleading Evidence in Observational Research,” Journal of the American Medical Association, 317, 705–707. DOI: 10.1001/jama.2016.19970.
   Web of Science ®Google Scholar
• He, H., Hu, J., and He, J. (2016), “Overview of Propensity Score Methods,” In Statistical Causal Inferences and Their Applications in Public Health Research”, eds. H. He, P. Wu, and C. Ding-Geng, available at DOI: 10.1007/978-3-319-41259-7.
   Google Scholar
• Hernán, M. A., and Robins, J. M. (2016), “Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available,” American Journal of Epidemiology, 183, 758–764. DOI: 10.1093/aje/kwv254.
   PubMed Web of Science ®Google Scholar
• Hernán, M.A., Sauer, B.C., Hernández-Díaz, S., Platt, R., and Shrier, I. (2016), “Specifying a Target Trial Prevents Immortal Time Bias and Other Self-Inflicted Injuries in Observational Analyses,” Journal of Clinical Epidemiology, 79, 70–75. DOI: 10.1016/j.jclinepi.2016.04.014.
   PubMed Web of Science ®Google Scholar
• Ho, M., van der Laan, M., Lee, H., Chen, J., Lee, K., Fang, Y., He, W., Irony, T., Jiang, Q., Lin, X., Meng, Z., Mishra-Kalyani, P., Rockhold, F., Song, Y., Wang, H., and White, R. (2021), “The Current Landscape in Biostatistics of Real-World Data and Evidence: Causal Inference Frameworks for Study Design and Analysis,” Statistics in Biopharmaceutical Research. DOI: 10.1080/19466315.2021.1883475.
   Web of Science ®Google Scholar
• ICH E9 (R1) (2019), “ICH E9(R1) Addendum on Estimands and Sensitivity Analyses in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials,” available at https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf
   Google Scholar
• Levenson, M., He, W., Chen, J., Fang, Y., Faries, D., Goldstein, B.A., Ho, M., Lee, K., Mishra-Kalyani, P., Rockhold, F., Wang, H. and Zink, R.C. (2021), “Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment,” Statistics in Biopharmaceutical Research. DOI: 10.1080/19466315.2021.1883473.
   Web of Science ®Google Scholar
• Li, Q., Lin, J., Chi, A., Davies, S. (2020), “Practical Considerations of Utilizing Propensity Score Methods in Clinical Development Using Real-World and Historical Data,” Contemporary Clinical Trials, 97, 106123. DOI: 10.1016/j.cct.2020.106123.
   PubMed Web of Science ®Google Scholar
• Phillippo, D. M., Dias, S., Ades, A. E., and Welton, N. J. (2020), “Assessing the Performance of Population Adjustment Methods for Anchored Indirect Comparisons: A Simulation Study,” Statistics in Medicine, 39, 4885–4911. DOI: 10.1002/sim.8759.
   PubMed Web of Science ®Google Scholar
• Phillips, A., Abellan-Andres, J., Soren, A., Bretz, F., Fletcher, C., France, L., Garrett, A., Harris, R., Kjaer, M., Keene, O., Morgan, D., O’Kelly, M., and Roger, J. (2017), “Estimands: Discussion Points From the PSI Estimands and Sensitivity Expert Group,” Pharmaceutical Statistics, 16, 6–11. DOI: 10.1002/pst.1745.
   PubMed Web of Science ®Google Scholar
• Rosenbaum, P. R., and Rubin, D. B. (1983), “The Central Role of the Propensity Score in Observational Studies for Causal Effects,” Biometrika, 70, 41–55. DOI: 10.1093/biomet/70.1.41.
   Web of Science ®Google Scholar
• Rosenbaum, P. R., and Rubin, D. B. (1984), “Reducing Bias in Observational Studies Using Subclassification on the Propensity Score,” Journal of the American Statistical Association, 79, 516–524. DOI: 10.1080/01621459.1984.10478078.
   Web of Science ®Google Scholar
• Williamson, E., Morley, R., Lucas, A. and Carpenter, J. (2011), “Propensity Scores: From Naive Enthusiasm to Intuitive Understanding,” Statistical Methods in Medical Research, 21, 273–293. DOI: 10.1177/0962280210394483.
   PubMed Web of Science ®Google Scholar